Dr. Goodman, My Mom is having a first recurrence 9 months after (carbo/taxotere) and her doctor is recommending a clinical trial for a monocular antibody called MOBAR. Its a study designed for women that have a rise in ca-125 and with a clear CT scan and are not symptomatic. He says shes a good candidate for that. Although her CT scan revealed an enlarged iliac chain lymph nodes 1x1.4 which is still in normal range. CA-125 slowly rising every few weeks. He says the recurrence is not aggressive. The clinical trial is meant to reduce the ca-125 for non symptomatic women and delay recurrence. Her current ca-125 is 26 as of last week, up by 7 within 3 weeks. His 2nd recommendation is back on carbo/taxotere. We are a little lost and not sure what to do. Im afraid if we dont get back onto chemo the cancer might progress if the clinical trial will not do anything for her. What would you recommend?
Another question I have is lets say if she does do carbo/taxotere and then she developes another recurrence in 9 months will carbo/taxotere not be an option for her again? Will it make her platinum resistant? Or your only platinum resistant if it comes back within 6 months no matter how many times you've taken the drugs in the past? Im asking because I want to know if we should reserve the platinum drugs for later and go with the clinical trial first.
What are your thoughts on this?
Thank you
-Fiana